(Q28182399)

full work available at URL

1

0 references

language of work or name

English

0 references

publication date

September 2003

0 references

https://api.elsevier.com/content/article/PII:S0149291803802813?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80281-3

https://api.elsevier.com/content/article/PII:S0149291803802813?httpAccept=text/plain

29 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80281-3

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

29 March 2024

published in

Clinical Therapeutics

0 references

volume

25

0 references

issue

9

0 references

page(s)

2352-87

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Triglycerides as a risk factor for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Evidence that triglycerides are an independent coronary heart disease risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Mechanistic studies of high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Low-density lipoprotein lowering therapy: an analysis of the options

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Management of dyslipidemia in the high-risk patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Long-term persistence in use of statin therapy in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Combination therapy for combined dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Treatment of hyperlipidemia with combined niacin-statin regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Combination therapy for dyslipidemia: safety and regulatory considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Rhabdomyolysis and HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Statin-fibrate combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

2-Azetidinones as inhibitors of cholesterol absorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

A target for cholesterol absorption inhibitors in the enterocyte brush border membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Identification of binding proteins for cholesterol absorption inhibitors as components of the intestinal cholesterol transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

The plasma concentration and LDL-C relationship in patients receiving ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Genetic basis of sitosterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980281-3

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

14

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80281-3

Novel approaches to lipid lowering: what is on the horizon?

29 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80281-3

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461

29 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80281-3

29 March 2024

Identifiers

release_br6rookhxfh3djngtlynyo5pea

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/br6rookhxfh3djngtlynyo5pea

24 November 2022